State MI
Clinical Trials in Michigan
Recruiting clinical trials with at least one study location in Michigan. Data updated daily from ClinicalTrials.gov.
Top Conditions in Michigan
Glioma (4)Advanced Solid Tumor (4)Multiple Myeloma (3)Rheumatoid Arthritis (3)Advanced Solid Tumors (3)Head and Neck Squamous Cell Carcinoma (2)Non-small Cell Lung Cancer (2)Oral Cavity Squamous Cell Carcinoma (2)Stage I Lip and Oral Cavity Cancer AJCC v8 (2)Stage II Lip and Oral Cavity Cancer AJCC v8 (2)Stroke (2)Multiple Sclerosis (2)
Frequently Asked Questions — Clinical Trials in Michigan
How many clinical trials are currently recruiting in Michigan?
ClinicalMetric currently tracks 164 actively recruiting clinical trials with at least one location in Michigan. The total number of registered studies—including active but not currently enrolling trials—is 164. Trial availability is updated daily from ClinicalTrials.gov, and new studies open enrollment regularly throughout the year.
What types of clinical trials are available in Michigan?
Michigan hosts clinical trials across a broad range of medical conditions, including Glioma, Advanced Solid Tumor, Multiple Myeloma, and many others. Trials range from Phase 1 early-safety studies to Phase 4 post-approval surveillance, as well as observational and behavioral research. Academic medical centers, community hospitals, and specialized research clinics throughout Michigan serve as trial sites for studies sponsored by NIH, pharmaceutical companies, and independent investigators.
How do I join a clinical trial near me in Michigan?
To join a clinical trial in Michigan, browse the recruiting studies listed on this page, review the eligibility criteria for each trial, and contact the study site directly. Your primary care physician or specialist can also refer you to clinical trials relevant to your diagnosis. Many academic medical centers in Michigan maintain dedicated clinical trials offices that can match you with appropriate studies based on your medical profile and diagnosis.
Recruiting Trials in Michigan
NCT06500702 Phase 2
Recruiting
A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzab...
Condition
Focal Segmental Glomerulosclerosis
Enrollment
84 pts
Location
United States, Argentina, Australia
Sponsor
Sanofi
NCT05355701 Phase 1
Recruiting
A Study to Learn About the Study Medicine Called PF-07799933 in People With Adva...
Condition
Melanoma
Enrollment
267 pts
Location
United States, Canada, Israel
Sponsor
Pfizer
NCT06258837 N/A
Recruiting
Treatment of Obstructive Sleep Apnea With Personalized Surgery in Children With ...
Condition
Otolaryngological Disease
Enrollment
240 pts
Location
United States
Sponsor
Oregon Health and Science Univ
NCT05866419 N/A
Recruiting
Study of an Intrathecal Port and Catheter System for Subjects With Spinal Muscul...
Condition
Spinal Muscular Atrophy
Enrollment
90 pts
Location
United States, Germany, Poland
Sponsor
Alcyone Therapeutics, Inc
NCT04333537 Phase 2, Phase 3
Recruiting
Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Pat...
Condition
Buccal Mucosa Squamous Cell Carcinoma
Enrollment
686 pts
Location
United States, Canada
Sponsor
NRG Oncology
NCT07298395 Phase 2
Recruiting
Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis
Condition
Atopic Dermatitis (AD)
Enrollment
60 pts
Location
United States
Sponsor
Enveda Therapeutics
NCT05894239 Phase 3
Recruiting
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Ph...
Condition
Metastatic Breast Cancer
Enrollment
230 pts
Location
United States, Argentina, Australia
Sponsor
Hoffmann-La Roche
NCT06395428 Phase 4
Recruiting
Haloperidol for Pain Control in Patients With Acute Musculoskeletal Back Pain in...
Condition
Back Pain
Enrollment
75 pts
Location
United States
Sponsor
Western Michigan University Sc
NCT02235857 N/A
Recruiting
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmen...
Condition
Focal Segmental Glomerulosclerosis
Enrollment
35 pts
Location
United States
Sponsor
Kaneka Medical America LLC
NCT06626919 Phase 1
Recruiting
A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With ...
Condition
Muscular Diseases
Enrollment
30 pts
Location
United States
Sponsor
Arcellx, Inc.
NCT06888921 Phase 1, Phase 2
Recruiting
A Clinical Trial to Evaluate the Safety and Efficacy of COM701 in Relapsed Plati...
Condition
Ovarian Cancer
Enrollment
60 pts
Location
United States, France, Israel
Sponsor
Compugen Ltd
NCT05424406 N/A
Recruiting
Role of Sleep Reactivity in Shift Work Disorder
Condition
Shift-work Disorder
Enrollment
150 pts
Location
United States
Sponsor
Henry Ford Health System
NCT06848348 Phase 2
Recruiting
Efficacy and Safety Study of Halneuron in the Treatment of Chemotherapy-Induced ...
Condition
Chemotherapy Induced Neuropathic Pain
Enrollment
200 pts
Location
United States
Sponsor
Dogwood Therapeutics Inc.
NCT04373317 Phase 4
Recruiting
Pimavanserin vs. Quetiapine for Treatment of Parkinson's Psychosis
Condition
Parkinson's Disease Psychosis
Enrollment
358 pts
Location
United States
Sponsor
VA Office of Research and Deve
NCT07285213 Phase 2
Recruiting
Prevention of Recurrent C. Difficile Infection Study With AZD5148 Monoclonal Ant...
Condition
Clostridioides Difficile Infection
Enrollment
230 pts
Location
United States, Australia, Canada
Sponsor
AstraZeneca
NCT06632457 Phase 3
Recruiting
LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a L...
Condition
Metabolic Dysfunction Associated Steatohepatitis
Enrollment
1,590 pts
Location
United States, Argentina, Australia
Sponsor
Boehringer Ingelheim
NCT06058377 Phase 3
Recruiting
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy T...
Condition
Anatomic Stage II Breast Cancer AJCC v8
Enrollment
3,680 pts
Location
United States, Puerto Rico
Sponsor
National Cancer Institute (NCI
NCT03488693 Phase 3
Recruiting
Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer
Condition
Breast Cancer
Enrollment
2,140 pts
Location
United States, Canada
Sponsor
Canadian Cancer Trials Group
NCT06559163 Phase 2
Recruiting
A Study of Obexelimab in Patients With Systemic Lupus Erythematosus
Condition
Systemic Lupus Erythematosus
Enrollment
190 pts
Location
United States, Belgium, Bulgaria
Sponsor
Zenas BioPharma (USA), LLC
NCT05126277 Phase 3
Recruiting
Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With ...
Condition
Lupus Nephritis
Enrollment
462 pts
Location
United States, Argentina, Brazil
Sponsor
Novartis Pharmaceuticals
NCT05339139 Phase 3
Recruiting
SAfety of Regional Citrate Anticoagulation (SARCA Study)
Condition
Acute Kidney Injury
Enrollment
50 pts
Location
United States
Sponsor
Fresenius Medical Care North A
NCT05874921 N/A
Recruiting
uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Canc...
Condition
Urothelial Carcinoma
Enrollment
400 pts
Location
United States
Sponsor
UroGen Pharma Ltd.
NCT05037968 N/A
Recruiting
MagnetOs Flex Matrix Compared to Trinity Elite Mixed With Local Autograft in Pat...
Condition
Degenerative Disc Disease
Enrollment
100 pts
Location
United States
Sponsor
Kuros Biosurgery AG
NCT06578247 Phase 3
Recruiting
Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-I...
Condition
Leukemia
Enrollment
700 pts
Location
United States, Australia, Austria
Sponsor
Daiichi Sankyo
NCT05985655 Phase 1, Phase 2
Recruiting
Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
Condition
Head and Neck Squamous Cell Carcinoma (HNSCC)
Enrollment
230 pts
Location
United States, Belgium, United Kingdom
Sponsor
Exscientia AI Ltd., a wholly o
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology